HPV SPECIFIC CELLULAR IMMUNITY IN CERVICAL INTRAEPITHELI

宫颈上皮内 HPV 特异性细胞免疫

基本信息

项目摘要

DESCRIPTION: (Adapted from the Investigator's Abstract) Epidemiological studies have clearly established that human papillomas (HPV) infection is a major risk factor for cervical cancer. A number of individuals undergo remission either spontaneously or after clinical intervention, while others, particularly those exhibiting immudeficiency, seem to proceed to develop invasive cancer. It is important to understand the immunological basis for the clinical remission of HPV-associated cervical neoplasia for designing proper intervention strategies. We have determined cell-mediated immunity (CMI) responses specific to synthetic peptides from E6 and E7, the two major oncoproteins of high risk type HPV (HPV-16), in a subset of patients attending the colposcopic clinic. These patients underwent excisional or ablative treatment for cervical intra epithelial neoplasia (CIN) at least six months prior to enrolling in the study. Significant differences were observed in proliferative responses directed against peptides from both the E6 (p=0.002) and E7 (p<0.001) between women without cytological or histological evidence of CIN (disease-free group) and those with a histological diagnosis of recurrence for CIN. Additional pilot studies on in vitro cytokine production mediated by the E6 and E7 peptides, showed a predominant TH1-cytokine profile in women from the disease-free group, while women with disease recurrence exhibited TH2-cytokine responses. On the other hand, none of the women in any of the study groups exhibited circulating antibodies reactive with the E6 and E7 peptides used in the study. Based on our results showing significantly high levels of HPV-peptide-specific TH1 responses in disease-free patients only, we hypothesize that HPV-specific CMI directed against the E6 and E7 oncoproteins is important for protection/recovery from HPV-associated CIN. To test this hypothesis, we propose to conduct a prospective cohort study of women positive for high-risk HPV types and treated for CIN by loop electrosurgical procedure. Our goals are to identify HPV peptides that can potentially serve as markers of protective immunity and for inclusion in immunotherapeutic and/or immunoprophylactic vaccine formulations against HPV-associated CIN. We will assess the pattern of the HPV-specific immunological responses over time, in particular CMI against E6 and E7 peptides corresponding to high-risk HPV types. We will also determine as to whether an association exists between the immune responses and additional HPV-related factors (persistence of infection and HPV type), and other risk factors associated with CIN such as smoking, sexual behavior, intrinsic and extrinsic hormonal factors.
描述:(改编自研究者摘要)流行病学研究 已经明确确定,人乳头状瘤(HPV)感染是一个主要的风险, 宫颈癌的病因一些人经历缓解, 自发或临床干预后,而其他人,特别是那些 表现出免疫缺陷,似乎继续发展为侵袭性癌症。是 重要的是要了解临床缓解的免疫学基础 HPV相关的宫颈肿瘤设计适当的干预策略。 我们已经确定了细胞介导的免疫(CMI)反应特异性合成 来自高危型HPV的两种主要癌蛋白E6和E7的肽 (HPV-16),在参加阴道镜诊所的患者亚组中。这些 例患者接受了宫颈内切除或消融治疗 在入组本研究前至少6个月患有上皮瘤变(CIN)。 在定向的增殖反应中观察到显著差异, 针对来自E6(p=0.002)和E7(p<0.001)的肽, 无CIN的细胞学或组织学证据(无病组), 组织学诊断为CIN复发的患者。附加导频 E6和E7肽介导的体外细胞因子产生的研究, 在无疾病组的女性中显示出占主导地位的TH 1-细胞因子谱, 而疾病复发的妇女表现出TH 2-细胞因子应答。上 另一方面,任何研究组中的女性都没有表现出循环 与研究中使用的E6和E7肽反应的抗体。基于我们 结果显示HPV-肽特异性TH 1应答的显著高水平 仅在无病患者中,我们假设HPV特异性CMI指导的 对E6和E7癌蛋白的保护/恢复是重要的 HPV相关CIN。为了验证这一假设,我们建议进行一次 高危型HPV阳性女性的前瞻性队列研究 用于宫颈上皮内瘤变。我们的目标是识别HPV 这些肽可以潜在地用作保护性免疫的标记物, 包含在免疫抑制剂和/或免疫预防性疫苗制剂中 HPV相关的CIN。我们将评估HPV特异性 随时间推移的免疫应答,特别是针对E6和E7肽的CMI 对应高危HPV类型。我们还将确定是否有 免疫反应与其他HPV相关的 因素(感染持续性和HPV类型)和其他风险因素 与CIN相关,如吸烟,性行为,内在和外在 荷尔蒙因素

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
  • DOI:
    10.1016/s0166-3542(02)00130-4
  • 发表时间:
    2002-12
  • 期刊:
  • 影响因子:
    7.6
  • 作者:
    P. Nehete;E. Vela;Mohammad M. Hossain;A. Sarkar;N. Yahi;J. Fantini;K. Sastry
  • 通讯作者:
    P. Nehete;E. Vela;Mohammad M. Hossain;A. Sarkar;N. Yahi;J. Fantini;K. Sastry
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jagannadha K Sastry其他文献

Jagannadha K Sastry的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jagannadha K Sastry', 18)}}的其他基金

Role of mucosal epithelial cells in HIV infection and pathology
粘膜上皮细胞在 HIV 感染和病理学中的作用
  • 批准号:
    8092097
  • 财政年份:
    2010
  • 资助金额:
    $ 45.17万
  • 项目类别:
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
  • 批准号:
    7849955
  • 财政年份:
    2009
  • 资助金额:
    $ 45.17万
  • 项目类别:
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
  • 批准号:
    7627172
  • 财政年份:
    2009
  • 资助金额:
    $ 45.17万
  • 项目类别:
Mucosal Immunization with a Conserved HIV Envelope Peptide Cocktail Vaccine
使用保守的 HIV 包膜肽混合物疫苗进行粘膜免疫
  • 批准号:
    7121765
  • 财政年份:
    2006
  • 资助金额:
    $ 45.17万
  • 项目类别:
Mucosal Immunization with a Conserved HIV Envelope Peptide Cocktail Vaccine
使用保守的 HIV 包膜肽混合物疫苗进行粘膜免疫
  • 批准号:
    7244130
  • 财政年份:
    2006
  • 资助金额:
    $ 45.17万
  • 项目类别:
HIV ENVELOPE PEPTIDE BASED VACCINE IN SHIV RHESUS MODEL
SHIV 恒河猴模型中的 HIV 包膜肽疫苗
  • 批准号:
    6147640
  • 财政年份:
    2000
  • 资助金额:
    $ 45.17万
  • 项目类别:
HIV ENVELOPE PEPTIDE BASED VACCINE IN SHIV RHESUS MODEL
SHIV 恒河猴模型中的 HIV 包膜肽疫苗
  • 批准号:
    6374418
  • 财政年份:
    2000
  • 资助金额:
    $ 45.17万
  • 项目类别:
HIV ENVELOPE PEPTIDE BASED VACCINE IN SHIV RHESUS MODEL
SHIV 恒河猴模型中的 HIV 包膜肽疫苗
  • 批准号:
    6511214
  • 财政年份:
    2000
  • 资助金额:
    $ 45.17万
  • 项目类别:
HIV Envelope Peptide-Based Vaccine in SHIV-Rhesus Model
SHIV-恒河猴模型中的 HIV 包膜肽疫苗
  • 批准号:
    7008828
  • 财政年份:
    1999
  • 资助金额:
    $ 45.17万
  • 项目类别:
HPV SPECIFIC CELLULAR IMMUNITY IN CERVICAL INTRAEPITHELI
宫颈上皮内 HPV 特异性细胞免疫
  • 批准号:
    6376685
  • 财政年份:
    1999
  • 资助金额:
    $ 45.17万
  • 项目类别:

相似海外基金

Urinary Phthalate Biomarker Concentrations and Breast and Prostate Cancer Risk in a National Cohort of Adults in Canada
加拿大全国成人队列中尿液邻苯二甲酸盐生物标志物浓度与乳腺癌和前列腺癌风险
  • 批准号:
    494953
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
    Operating Grants
Prospective metabolomics investigation of gastric cancer risk in African Americans and European Whites with a low socioeconomic status
社会经济地位较低的非裔美国人和欧洲白人胃癌风险的前瞻性代谢组学调查
  • 批准号:
    10912190
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
Deep Learning Image Analysis Algorithms to Improve Oral Cancer Risk Assessment for Oral Potentially Malignant Disorders
深度学习图像分析算法可改善口腔潜在恶性疾病的口腔癌风险评估
  • 批准号:
    10805177
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
  • 批准号:
    10719777
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
Developing diagnostics of patient-specific cancer risk and early-stage tumorigenesis
开发患者特异性癌症风险和早期肿瘤发生的诊断方法
  • 批准号:
    478999
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
    Operating Grants
Environmental Metal Exposures and Breast Cancer Risk: A Prospective Study of Nationally Representative Canadian Data
环境金属暴露与乳腺癌风险:加拿大全国代表性数据的前瞻性研究
  • 批准号:
    495159
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
Mechanisms of tamoxifen-associated endometrial cancer risk
他莫昔芬相关子宫内膜癌风险的机制
  • 批准号:
    10650054
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
Gut microbiota-related mechanisms that impact colorectal cancer risk after bariatric surgery
影响减肥手术后结直肠癌风险的肠道微生物相关机制
  • 批准号:
    10733566
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
Obesity, body fat distribution, and breast cancer risk: is visceral fat the culprit after menopause?
肥胖、身体脂肪分布和乳腺癌风险:内脏脂肪是绝经后的罪魁祸首吗?
  • 批准号:
    10586626
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
Optimization of a personalized skin cancer risk intervention for at-risk young adults
针对高危年轻人的个性化皮肤癌风险干预措施的优化
  • 批准号:
    10582944
  • 财政年份:
    2023
  • 资助金额:
    $ 45.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了